UVP is Now an Analytik Jena Company
News Apr 18, 2013
Analytik Jena AG, based in Jena, Germany has acquired all of the outstanding shares of Upland, California based UVP, LLC including its subsidiary, Ultra-Violet Products, Ltd., located in Cambridge UK.
UVP is a leading manufacturer of bioimaging systems for applications in proteomics, genomics, plant and animal sciences.
The company also manufactures ultraviolet products, light sources, and laboratory equipment such as hybridization ovens, transilluminators, crosslinkers and PCR hoods.
The acquisition of UVP, LLC allows Analytik Jena to strengthen its presence in the US market and expand its product portfolio.
"With the acquisition of UVP, we are significantly expanding our business activities in the Life Science unit and are laying an excellent basis for developing our successful business model in the USA and neighboring regions. Here, we are combining efficient sales structures, a well-coordinated product portfolio and broad technological expertise in the respective core segments. Further extensive synergies are to arise, especially in sales in Europe and Asia. With UVP, Analytik Jena also gains a production plant in the US dollar currency area." says Klaus Berka, CEO of Analytik Jena AG.
Analytik Jena is a provider of modern analytical technology, life science systems for bioanalytical applications, and high-end optical consumer products.
With the integration of UVP into Analytik Jena's Life Science business unit, numerous synergies are expected.
According to Leighton Smith, UVP’s President and CEO, “UVP has an opportunity to contribute significantly to the growth and profitability of Analytik Jena’s Life Science business unit. Our combined manufacturing expertise, portfolio of products and distribution channels open up new market opportunities, and begins an exciting new chapter in UVP’s history of providing innovative products and solutions to our customers.”
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.